Evidence that delayed growth at distant tumor sites depends on CD8+ T cells following pre-resectional RFA is further in line with clinical observations of systemic tumor control after RFA treatment in renal cell carcinoma and prostate cancer patients [16–18]. The gene discussed is CD8A; the disease is renal cell carcinoma.